Do weight-loss drugs actually save employers money on healthcare costs?

Employers are divided on whether covering GLP-1 medications like Wegovy and Zepbound will reduce long-term medical expenses. This episode examines the financial logic behind these benefits and whether the investment in weight-loss drugs leads to lower costs elsewhere.

While most employer health plans currently exclude GLP-1s for weight loss, approximately 20% of plans have opted to provide coverage. These employers often operate under the assumption that by helping employees manage obesity, they will reduce the need for expensive medical treatments associated with weight-related health issues.

The core question remains whether these drugs can deliver a positive return on investment for companies. The episode explores the economic reality of this gamble, weighing the high cost of the medication against the potential for future healthcare savings.

Source: Why GLP-1s aren't lowering employers' costs | The Indicator